marketcaparena
Search

    PCRX

    Pacira BioSciences, Inc.

    Company overview

    Market capitalization
    $1.01B
    Employees
    825
    Latest publication
    2026-09-29
    About Pacira BioSciences, Inc.

    Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ2 20242024-06-30 · USD
    Total Revenue192,399,000USD177,376,000USD196,873,000USD179,516,000USD181,099,000USD168,923,000USD187,253,000USD178,023,000USD
    Cost Of Revenue44,164,000USD36,413,000USD40,299,000USD34,278,000USD40,866,000USD34,306,000USD39,886,000USD44,262,000USD
    Gross Profit148,235,000USD140,963,000USD156,574,000USD145,238,000USD140,233,000USD134,617,000USD147,367,000USD133,761,000USD
    Research Development30,243,000USD28,072,000USD37,453,000USD25,966,000USD28,200,000USD25,342,000USD23,897,000USD20,338,000USD
    Selling General Administrative91,809,000USD35,778,000USD39,998,000USD33,326,000USD37,614,000USD31,205,000USD29,272,000USD29,079,000USD
    Other Operating Expenses14,322,000USD———————
    Total Operating Expenses143,968,000USD136,338,000USD153,383,000USD138,876,000USD131,734,000USD132,627,000USD122,663,000USD105,521,000USD
    Operating Income4,267,000USD4,625,000USD3,191,000USD6,362,000USD8,499,000USD1,990,000USD24,704,000USD28,240,000USD
    Total Other Income Expense Net-1,712,000USD373,000USD-2,620,000USD3,162,000USD-10,426,000USD6,716,000USD822,000USD8,344,000USD
    Interest Income1,944,000USD1,930,000USD2,295,000USD8,534,000USD5,008,000USD6,895,000USD5,555,000USD4,749,000USD
    Interest Expense3,622,000USD3,178,000USD3,372,000USD3,653,000USD4,695,000USD4,580,000USD3,834,000USD3,121,000USD
    Income Before Tax2,555,000USD4,998,000USD571,000USD9,524,000USD-1,927,000USD8,706,000USD25,526,000USD36,584,000USD
    Income Tax Expense-2,098,000USD2,082,000USD-1,066,000USD4,092,000USD2,920,000USD3,894,000USD9,485,000USD17,698,000USD
    Net Income4,653,000USD2,916,000USD1,637,000USD5,432,000USD-4,847,000USD4,812,000USD16,041,000USD18,886,000USD
    Selling And Marketing Expenses—58,166,000USD61,610,000USD58,471,000USD50,964,000USD55,571,000USD50,342,000USD39,047,000USD
    Unclassified Operating Expenses—14,322,000USD14,322,000USD21,113,000USD14,956,000USD20,509,000USD19,152,000USD17,057,000USD
    Net Interest Income—-1,769,000USD-1,597,000USD4,255,000USD313,000USD2,315,000USD875,000USD865,000USD
    Tax Provision—2,082,000USD-1,066,000USD4,092,000USD2,920,000USD3,894,000USD9,485,000USD17,698,000USD
    Net Income From Continuing Ops—2,916,000USD1,637,000USD5,432,000USD-4,847,000USD4,812,000USD16,041,000USD18,886,000USD
    Ebit—8,176,000USD3,943,000USD13,177,000USD1,919,000USD12,441,000USD29,360,000USD39,705,000USD
    Ebitda—29,507,000USD25,285,000USD34,368,000USD29,241,000USD33,609,000USD50,603,000USD58,568,000USD
    Depreciation And Amortization—21,331,000USD21,342,000USD21,191,000USD27,322,000USD21,168,000USD21,243,000USD18,863,000USD
    Reconciled Depreciation—21,331,000USD21,342,000USD21,191,000USD27,322,000USD21,168,000USD21,243,000USD18,863,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USDFY 20152015-12-31 · USD
    Total Revenue726,411,000USD674,978,000USD666,823,000USD541,533,000USD429,647,000USD421,026,000USD337,277,000USD248,997,000USD
    Cost Of Revenue149,749,000USD184,669,000USD199,295,000USD140,255,000USD117,328,000USD106,712,000USD86,845,000USD71,837,000USD
    Gross Profit576,662,000USD490,309,000USD467,528,000USD401,278,000USD312,319,000USD314,314,000USD250,432,000USD177,160,000USD
    Research Development117,312,000USD76,257,000USD84,797,000USD55,545,000USD59,421,000USD72,119,000USD55,688,000USD28,662,000USD
    Selling General Administrative142,143,000USD116,401,000USD109,520,000USD88,323,000USD74,834,000USD71,119,000USD70,159,000USD61,310,000USD
    Selling And Marketing Expenses226,616,000USD153,040,000USD144,996,000USD111,022,000USD118,682,000USD129,663,000USD107,106,000USD77,733,000USD
    Unclassified Operating Expenses57,288,000USD56,936,000USD68,191,000USD56,464,000USD13,032,000USD30,933,000USD——
    Total Operating Expenses543,359,000USD402,634,000USD407,504,000USD311,354,000USD265,969,000USD303,834,000USD232,953,000USD167,705,000USD
    Operating Income33,303,000USD87,675,000USD60,024,000USD89,924,000USD46,350,000USD10,480,000USD15,915,000USD9,455,000USD
    Interest Income22,732,000USD10,804,000USD4,542,000USD896,000USD4,629,000USD7,376,000USD6,497,000USD7,047,000USD
    Interest Expense14,606,000USD17,310,000USD35,576,000USD28,996,000USD25,671,000USD23,628,000USD21,949,000USD7,725,000USD
    Net Interest Income5,286,000USD-17,155,000USD-35,434,000USD-30,854,000USD-21,042,000USD-16,252,000USD-15,452,000USD—
    Income Before Tax16,874,000USD61,701,000USD13,302,000USD56,404,000USD20,089,000USD-10,748,000USD-425,000USD2,120,000USD
    Income Tax Expense9,840,000USD19,746,000USD-2,607,000USD14,424,000USD-125,434,000USD268,000USD46,000USD264,000USD
    Tax Provision9,840,000USD2,930,000USD-2,607,000USD14,424,000USD-125,434,000USD268,000USD46,000USD264,000USD
    Net Income7,034,000USD41,955,000USD15,909,000USD41,980,000USD145,523,000USD-11,016,000USD-471,000USD1,856,000USD
    Net Income From Continuing Ops7,034,000USD6,983,000USD15,909,000USD41,980,000USD145,523,000USD-11,016,000USD-471,000USD1,856,000USD
    Ebit31,480,000USD79,011,000USD48,878,000USD85,400,000USD43,604,000USD11,173,000USD19,890,000USD9,916,000USD
    Ebitda122,503,000USD154,585,000USD140,379,000USD113,948,000USD63,512,000USD30,749,000USD33,055,000USD21,391,000USD
    Depreciation And Amortization91,023,000USD75,574,000USD91,501,000USD28,548,000USD19,908,000USD19,576,000USD13,165,000USD11,475,000USD
    Reconciled Depreciation91,023,000USD87,495,000USD91,501,000USD13,553,000USD19,908,000USD19,576,000USD13,165,000USD—
    Total Other Income Expense Net-16,429,000USD-25,974,000USD-46,722,000USD-33,520,000USD-26,261,000USD-21,228,000USD-16,340,000USD-7,335,000USD
    Net Income Applicable To Common Shares——15,909,000USD41,980,000USD145,523,000USD-11,016,000USD-471,000USD1,856,000USD
    Non Operating Income Net Other———-1,770,000USD-590,000USD2,400,000USD5,609,000USD390,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets1,243,978,000USD1,208,534,000USD1,264,917,000USD1,297,577,000USD1,537,262,000USD1,586,669,000USD1,553,516,000USD1,521,691,000USD
    Cash And Equivalents205,875,000USD———————
    Cash And Short Term Investments251,031,000USD202,180,000USD238,424,000USD246,334,000USD445,864,000USD493,626,000USD484,615,000USD453,810,000USD
    Short Term Investments45,156,000USD57,874,000USD79,879,000USD98,745,000USD145,380,000USD210,016,000USD207,841,000USD207,845,000USD
    Total Current Assets615,215,000USD514,961,000USD547,974,000USD562,751,000USD745,613,000USD759,962,000USD745,130,000USD689,969,000USD
    Other Current Assets29,852,000USD36,776,000USD32,618,000USD43,269,000USD37,219,000USD27,837,000USD21,929,000USD23,641,000USD
    Total Liabilities572,002,000USD———————
    Total Current Liabilities122,011,000USD108,787,000USD120,590,000USD107,078,000USD313,164,000USD314,732,000USD309,920,000USD306,401,000USD
    Other Current Liabilities93,499,000USD———————
    Other Non Current Liabilities26,650,000USD———————
    Total Stockholder Equity671,976,000USD653,893,000USD693,111,000USD727,214,000USD757,767,000USD798,541,000USD778,348,000USD749,583,000USD
    Total Equity Including Noncontrolling Interest671,976,000USD———————
    Long Term Debt363,124,000USD367,656,000USD372,189,000USD376,721,000USD378,095,000USD381,290,000USD383,545,000USD385,891,000USD
    Net Receivables132,420,000USD125,635,000USD124,069,000USD115,468,000USD114,367,000USD104,745,000USD113,304,000USD100,653,000USD
    Inventory134,575,000USD150,370,000USD152,863,000USD157,680,000USD148,163,000USD133,754,000USD125,282,000USD111,865,000USD
    Property Plant Equipment Net175,197,000USD175,690,000USD182,467,000USD191,654,000USD201,706,000USD213,179,000USD216,391,000USD220,682,000USD
    Goodwill19,642,000USD———————
    Intangible Assets285,484,000USD353,227,000USD368,100,000USD382,396,000USD422,563,000USD434,969,000USD425,970,000USD440,292,000USD
    Accounts Payable17,509,000USD14,012,000USD15,150,000USD17,687,000USD30,124,000USD23,172,000USD19,133,000USD19,367,000USD
    Short Term Debt10,298,000USD9,818,000USD9,839,000USD9,748,000USD212,017,000USD211,491,000USD210,663,000USD210,657,000USD
    Common Stock49,000USD48,000USD48,000USD48,000USD48,000USD47,000USD47,000USD47,000USD
    Retained Earnings-191,753,000USD-196,406,000USD-199,322,000USD-200,959,000USD-206,391,000USD-201,544,000USD-206,356,000USD-222,397,000USD
    Accumulated Other Comprehensive Income3,241,000USD3,455,000USD4,327,000USD4,123,000USD4,062,000USD1,351,000USD343,000USD678,000USD
    Total Liab—554,641,000USD571,806,000USD570,363,000USD779,495,000USD788,128,000USD775,168,000USD772,108,000USD
    Other Current Liab—84,957,000USD95,601,000USD79,643,000USD71,023,000USD80,069,000USD80,124,000USD76,377,000USD
    Capital Stock—48,000USD48,000USD48,000USD48,000USD47,000USD47,000USD47,000USD
    Good Will—19,773,000USD20,214,000USD20,317,000USD20,300,000USD21,520,000USD0USD0USD
    Cash—144,306,000USD158,545,000USD147,589,000USD300,484,000USD283,610,000USD276,774,000USD245,965,000USD
    Net Debt—266,873,000USD295,835,000USD277,719,000USD330,919,000USD352,849,000USD362,079,000USD398,458,000USD
    Short Long Term Debt Total—411,179,000USD454,380,000USD425,308,000USD631,403,000USD636,459,000USD638,853,000USD644,423,000USD
    Property Plant Equipment Gross—320,400,000USD320,170,000USD324,319,000USD354,481,000USD352,954,000USD349,320,000USD350,409,000USD
    Common Stock Shares Outstanding—40,910,000shares42,981,000shares44,459,000shares45,459,000shares46,526,000shares49,036,000shares46,134,000shares
    Non Current Assets Total—693,573,000USD716,943,000USD734,826,000USD791,649,000USD826,707,000USD808,386,000USD831,722,000USD
    Non Current Liabilities Total—445,854,000USD451,216,000USD463,285,000USD466,331,000USD473,396,000USD465,248,000USD465,707,000USD
    Non Current Liabilities Other—40,400,000USD38,638,000USD43,138,000USD42,362,000USD41,432,000USD37,058,000USD31,941,000USD
    Non Currrent Assets Other—22,768,000USD22,308,000USD20,271,000USD—28,031,000USD35,649,000USD—
    Net Working Capital—406,174,000USD427,384,000USD455,673,000USD432,449,000USD445,230,000USD435,210,000USD383,568,000USD
    Unclassified Non Current Assets—122,115,000USD123,854,000USD99,917,000USD128,270,000USD100,977,000USD130,376,000USD134,022,000USD
    Unclassified Non Current Liabilities—37,798,000USD40,389,000USD43,426,000USD45,874,000USD50,674,000USD44,645,000USD47,875,000USD
    Unclassified Equity—846,748,000USD888,010,000USD923,954,000USD960,000,000USD998,640,000USD984,267,000USD971,208,000USD
    Long Term Investments———20,271,000USD18,810,000USD28,031,000USD0USD36,726,000USD
    Short Long Term Debt————202,397,000USD202,086,000USD201,776,000USD201,466,000USD
    Unclassified Current Liabilities————-202,397,000USD-202,086,000USD-201,776,000USD-201,466,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets1,264,917,000USD1,553,516,000USD1,574,386,000USD1,681,200,000USD2,075,353,000USD1,274,513,000USD831,065,000USD689,353,000USD
    Intangible Assets368,100,000USD425,970,000USD483,258,000USD540,546,000USD623,968,000USD96,521,000USD104,387,000USD—
    Other Current Assets32,618,000USD21,929,000USD21,504,000USD15,223,000USD14,771,000USD12,265,000USD10,781,000USD15,892,000USD
    Total Liab571,806,000USD775,168,000USD704,256,000USD906,190,000USD1,344,945,000USD654,825,000USD476,121,000USD368,127,000USD
    Total Stockholder Equity693,111,000USD778,348,000USD870,130,000USD775,010,000USD730,408,000USD619,688,000USD354,944,000USD321,226,000USD
    Other Current Liab95,601,000USD80,124,000USD64,243,000USD89,785,000USD127,555,000USD85,710,000USD88,606,000USD45,865,000USD
    Common Stock48,000USD47,000USD46,000USD46,000USD45,000USD44,000USD42,000USD41,000USD
    Capital Stock48,000USD47,000USD46,000USD46,000USD45,000USD44,000USD42,000USD41,000USD
    Retained Earnings-199,322,000USD-206,356,000USD-106,796,000USD-148,751,000USD-211,895,000USD-253,875,000USD-399,398,000USD-388,226,000USD
    Good Will20,214,000USD0USD163,243,000USD163,243,000USD145,175,000USD99,547,000USD99,547,000USD62,040,000USD
    Cash158,545,000USD276,774,000USD153,298,000USD104,139,000USD585,578,000USD99,957,000USD78,228,000USD132,526,000USD
    Cash And Short Term Investments238,424,000USD484,615,000USD278,581,000USD288,651,000USD656,409,000USD521,662,000USD291,950,000USD383,454,000USD
    Total Current Assets547,974,000USD745,130,000USD509,994,000USD498,334,000USD866,048,000USD651,623,000USD408,557,000USD477,969,000USD
    Total Current Liabilities120,590,000USD309,920,000USD97,383,000USD147,774,000USD521,118,000USD253,328,000USD107,673,000USD60,661,000USD
    Net Debt295,835,000USD362,079,000USD432,746,000USD659,255,000USD543,270,000USD441,171,000USD273,690,000USD158,404,000USD
    Short Term Debt9,839,000USD210,663,000USD17,442,000USD42,769,000USD382,591,000USD157,073,000USD4,935,000USD338,000USD
    Short Long Term Debt Total454,380,000USD638,853,000USD586,044,000USD763,394,000USD1,128,848,000USD541,128,000USD351,918,000USD290,930,000USD
    Long Term Debt372,189,000USD383,545,000USD513,796,000USD655,823,000USD674,530,000USD313,030,000USD306,045,000USD290,592,000USD
    Short Term Investments79,879,000USD207,841,000USD125,283,000USD184,512,000USD70,831,000USD421,705,000USD213,722,000USD250,928,000USD
    Net Receivables124,069,000USD113,304,000USD105,556,000USD98,397,000USD96,318,000USD53,046,000USD47,530,000USD38,000,000USD
    Inventory152,863,000USD125,282,000USD104,353,000USD96,063,000USD98,550,000USD64,650,000USD58,296,000USD48,569,000USD
    Accounts Payable15,150,000USD19,133,000USD15,698,000USD15,220,000USD10,543,000USD10,431,000USD12,799,000USD14,368,000USD
    Property Plant Equipment Net182,467,000USD216,391,000USD234,947,000USD254,389,000USD264,811,000USD211,180,000USD142,805,000USD108,670,000USD
    Property Plant Equipment Gross320,170,000USD349,320,000USD370,253,000USD254,389,000USD264,811,000USD211,180,000USD142,805,000USD108,670,000USD
    Accumulated Other Comprehensive Income4,327,000USD343,000USD247,000USD-380,000USD167,000USD318,000USD322,000USD-280,000USD
    Common Stock Shares Outstanding45,042,000shares46,245,000shares51,979,000shares46,538,000shares45,630,000shares43,682,000shares41,513,000shares40,911,000shares
    Non Current Assets Total716,943,000USD808,386,000USD1,064,392,000USD1,182,866,000USD1,209,305,000USD622,890,000USD422,508,000USD211,384,000USD
    Non Current Liabilities Total451,216,000USD465,248,000USD606,873,000USD758,416,000USD823,827,000USD401,497,000USD368,448,000USD307,466,000USD
    Non Current Liabilities Other38,638,000USD37,058,000USD38,271,000USD37,791,000USD67,445,000USD88,467,000USD62,403,000USD16,874,000USD
    Non Currrent Assets Other22,308,000USD6,200,000USD36,049,000USD27,170,000USD21,987,000USD14,019,000USD10,971,000USD657,000USD
    Net Working Capital427,384,000USD435,210,000USD412,611,000USD350,560,000USD344,930,000USD398,295,000USD300,884,000USD417,308,000USD
    Unclassified Non Current Assets123,854,000USD159,825,000USD144,484,999USD-27,170,000USD-21,987,000USD-197,989,000USD—13,443,000USD
    Unclassified Non Current Liabilities40,389,000USD44,645,000USD54,806,000USD27,011,000USD—-17,442,000USD-21,465,000USD-16,874,000USD
    Unclassified Equity888,010,000USD984,267,000USD976,587,000USD924,049,000USD942,046,000USD873,157,000USD753,936,000USD709,650,000USD
    Short Long Term Debt—201,776,000USD8,641,000USD33,648,000USD374,700,000USD149,648,000USD—338,000USD
    Long Term Investments—0USD2,410,000USD64,379,000USD21,987,000USD109,478,000USD64,798,000USD25,871,000USD
    Unclassified Current Liabilities—-201,776,000USD-42,676,000USD-33,648,000USD-384,396,000USD-220,622,000USD-70,427,000USD—
    Other Assets——1USD160,309,000USD153,364,000USD290,134,000USD971,000USD703,000USD
    Current Deferred Revenue——34,035,000USD—10,125,000USD71,088,000USD71,760,000USD—
    Other Liab———37,791,000USD77,570,000USD17,442,000USD21,465,000USD16,874,000USD
    Net Tangible Assets———71,221,000USD-38,735,000USD423,620,000USD151,010,000USD259,186,000USD
    Unclassified Current Assets———————-7,946,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income2,916,000USD1,637,000USD5,432,000USD-4,847,000USD4,812,000USD16,041,000USD-143,466,000USD18,886,000USD
    Depreciation21,331,000USD21,342,000USD21,191,000USD27,322,000USD21,168,000USD21,243,000USD20,253,000USD18,863,000USD
    Stock Based Compensation13,539,000USD13,499,000USD13,978,000USD15,472,000USD14,553,000USD12,266,000USD13,230,000USD12,524,000USD
    Other Non Cash Items-11,950,000USD-3,752,000USD28,156,000USD11,515,000USD-7,695,000USD4,406,000USD160,700,000USD-5,187,000USD
    Change To Account Receivables-1,567,000USD-8,799,000USD-897,000USD-9,605,000USD8,559,000USD-12,651,000USD4,127,000USD-3,141,000USD
    Change To Inventory2,491,000USD4,817,000USD-9,513,000USD-14,399,000USD-8,472,000USD-13,417,000USD-8,427,000USD-6,657,000USD
    Change In Working Capital-1,886,000USD14,707,000USD-15,995,000USD-38,202,000USD1,224,000USD-24,332,000USD2,088,000USD-4,385,000USD
    Total Cash From Operating Activities25,680,000USD43,689,000USD60,834,000USD12,012,000USD35,459,000USD33,132,000USD53,920,000USD53,236,000USD
    Capital Expenditures-2,724,000USD-218,000USD-3,870,000USD-2,697,000USD-8,548,000USD-2,118,000USD-4,092,000USD-1,590,000USD
    Free Cash Flow22,956,000USD43,471,000USD56,964,000USD9,315,000USD26,911,000USD31,014,000USD49,828,000USD51,646,000USD
    Investments22,500,000USD19,551,000USD43,614,000USD62,163,000USD-25,629,000USD-368,000USD-52,163,000USD-15,215,000USD
    Total Cashflows From Investing Activities19,441,000USD19,333,000USD43,614,000USD62,163,000USD-25,629,000USD-368,000USD-52,163,000USD-15,215,000USD
    Net Borrowings-5,000,000USD-5,000,000USD-205,236,000USD-3,750,000USD-2,813,000USD-2,812,000USD-2,813,000USD—
    Total Cash From Financing Activities-59,398,000USD-51,652,000USD-257,476,000USD-57,505,000USD-2,994,000USD-1,955,000USD-2,845,000USD24,980,000USD
    Sale Purchase Of Stock-50,045,000USD-48,248,000USD-50,041,000USD-50,039,000USD0USD0USD25,004,000USD-25,000,000USD
    Change In Cash-14,239,000USD10,956,000USD-152,895,000USD16,874,000USD6,836,000USD30,809,000USD-1,088,000USD63,001,000USD
    Begin Period Cash Flow158,545,000USD147,589,000USD300,484,000USD283,610,000USD276,774,000USD245,965,000USD247,053,000USD184,052,000USD
    End Period Cash Flow144,306,000USD158,545,000USD147,589,000USD300,484,000USD283,610,000USD276,774,000USD245,965,000USD247,053,000USD
    Other Cashflows From Financing Activities-4,355,000USD-143,000USD-2,199,000USD-5,285,000USD-181,000USD857,000USD-32,000USD-378,000USD
    Unclassified Operating Cash Flow1,730,000USD-3,744,000USD8,072,000USD—1,397,000USD3,508,000USD1,115,000USD12,535,000USD
    Other Cashflows From Investing Activities—4,927,000USD—————-13,625,000USD
    Unclassified Investing Cash Flow—-4,927,000USD3,870,000USD2,697,000USD8,548,000USD2,118,000USD4,092,000USD15,215,000USD
    Unclassified Financing Cash Flow—1,739,000USD—1,569,000USD——-25,004,000USD50,358,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income7,034,000USD-99,560,000USD41,955,000USD15,909,000USD41,980,000USD145,523,000USD-11,016,000USD-471,000USD
    Depreciation91,023,000USD78,785,000USD75,574,000USD91,501,000USD28,548,000USD19,908,000USD19,576,000USD13,165,000USD
    Stock Based Compensation57,502,000USD51,171,000USD47,895,000USD48,092,000USD42,246,000USD39,920,000USD33,650,000USD31,725,000USD
    Other Non Cash Items28,224,000USD156,891,000USD19,387,000USD14,150,000USD20,745,000USD22,680,000USD31,755,000USD14,389,000USD
    Change To Account Receivables-10,742,000USD-7,748,000USD-7,159,000USD-2,079,000USD-10,434,000USD-5,516,000USD-8,524,000USD-5,999,000USD
    Change To Inventory-27,567,000USD-20,929,000USD-8,290,000USD2,486,000USD-4,467,000USD-6,353,000USD-8,026,000USD-7,157,000USD
    Change In Working Capital-38,266,000USD-18,519,000USD-45,777,000USD-16,433,000USD-18,674,000USD-24,386,000USD-8,770,000USD-10,857,000USD
    Total Cash From Operating Activities151,994,000USD189,389,000USD154,649,000USD145,274,000USD125,717,000USD77,032,000USD70,520,000USD48,870,000USD
    Capital Expenditures-15,333,000USD-10,636,000USD-15,161,000USD-30,076,000USD-45,866,000USD-37,801,000USD-10,159,000USD-14,514,000USD
    Free Cash Flow136,661,000USD178,753,000USD139,488,000USD115,198,000USD79,851,000USD39,231,000USD60,361,000USD34,356,000USD
    Investments131,516,000USD-83,276,000USD80,356,000USD-225,185,000USD449,118,000USD-239,806,000USD984,000USD41,933,000USD
    Total Cashflows From Investing Activities99,481,000USD-83,276,000USD77,541,000USD-225,185,000USD-20,790,000USD-277,607,000USD-128,488,000USD20,576,000USD
    Net Borrowings-216,799,000USD76,615,000USD-180,762,000USD-427,694,000USD363,750,000USD125,428,000USD-338,000USD-338,000USD
    Total Cash From Financing Activities-369,627,000USD17,363,000USD-183,031,000USD-401,528,000USD380,694,000USD222,304,000USD3,670,000USD8,954,000USD
    Sale Purchase Of Stock-148,328,000USD-25,000,000USD-106,000USD2,954,000USD2,811,000USD45,218,000USD8,469,000USD7,170,000USD
    Change In Cash-118,229,000USD123,476,000USD49,159,000USD-481,439,000USD485,621,000USD21,729,000USD-54,298,000USD78,400,000USD
    Begin Period Cash Flow276,774,000USD153,298,000USD104,139,000USD585,578,000USD99,957,000USD78,228,000USD132,526,000USD54,126,000USD
    End Period Cash Flow158,545,000USD276,774,000USD153,298,000USD104,139,000USD585,578,000USD99,957,000USD78,228,000USD132,526,000USD
    Other Cashflows From Investing Activities4,927,000USD——-32,000,000USD-424,042,000USD-239,806,000USD-119,313,000USD157,000USD
    Other Cashflows From Financing Activities-5,617,000USD-34,252,000USD-2,163,000USD-1,175,000USD380,556,000USD433,804,000USD8,323,000USD8,954,000USD
    Unclassified Operating Cash Flow6,477,000USD20,621,000USD15,615,000USD-7,945,000USD10,872,000USD-126,613,000USD5,325,000USD—
    Unclassified Investing Cash Flow-21,629,000USD10,636,000USD12,346,000USD62,076,000USD—239,806,000USD—-7,000,000USD
    Dividends Paid——-2,811,000USD—-2,673,000USD-1,618,000USD-4,315,000USD—
    Unclassified Financing Cash Flow——2,811,000USD24,387,000USD-363,750,000USD-380,528,000USD-8,469,000USD-6,832,000USD
    Change To Liabilities———6,272,000USD-10,137,000USD-11,778,000USD11,665,000USD5,527,000USD
    Cash And Cash Equivalents Changes————485,621,000USD21,729,000USD-54,298,000USD78,400,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30ProductBupivacaine Liposome Injectable Suspension3,216,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductEXPAREL147,823,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductIovera6,806,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductRoyalty1,906,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductZILRETTA32,648,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductBupivacaine Liposome Injectable Suspension1,159,000USD0001628280-26-028871
    Q1 2026Quarterly · 2026-03-31ProductEXPAREL143,274,000USD0001628280-26-028871
    Q1 2026Quarterly · 2026-03-31ProductIovera6,176,000USD0001628280-26-028871
    Q1 2026Quarterly · 2026-03-31ProductRoyalty0USD0001628280-26-028871
    Q1 2026Quarterly · 2026-03-31ProductZILRETTA26,767,000USD0001628280-26-028871
    Q4 2025Quarterly · 2025-12-31ProductBupivacaine Liposome Injectable Suspension1,110,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductEXPAREL155,782,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductIovera7,002,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductRoyalty0USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductZILRETTA32,979,000USDLegacy provider
    FY 2025Yearly · 2025-12-31ProductBupivacaine Liposome Injectable Suspension6,913,000USD0001628280-26-012297
    FY 2025Yearly · 2025-12-31ProductEXPAREL575,130,000USD0001628280-26-012297
    FY 2025Yearly · 2025-12-31ProductIovera24,178,000USD0001628280-26-012297
    FY 2025Yearly · 2025-12-31ProductRoyalty3,557,000USD0001628280-26-012297
    FY 2025Yearly · 2025-12-31ProductZILRETTA116,633,000USD0001628280-26-012297
    Q3 2025Quarterly · 2025-09-30ProductBupivacaine Liposome Injectable Suspension2,691,000USD0001628280-25-050176
    Q3 2025Quarterly · 2025-09-30ProductEXPAREL139,902,000USD0001628280-25-050176
    Q3 2025Quarterly · 2025-09-30ProductIovera6,465,000USD0001628280-25-050176
    Q3 2025Quarterly · 2025-09-30ProductRoyalty1,476,000USD0001628280-25-050176
    Q3 2025Quarterly · 2025-09-30ProductZILRETTA28,982,000USD0001628280-25-050176
    Q2 2025Quarterly · 2025-06-30ProductBupivacaine Liposome Injectable Suspension508,000USD0001396814-25-000102
    Q2 2025Quarterly · 2025-06-30ProductEXPAREL142,917,000USD0001396814-25-000102
    Q2 2025Quarterly · 2025-06-30ProductIovera5,588,000USD0001396814-25-000102
    Q2 2025Quarterly · 2025-06-30ProductRoyalty752,000USD0001396814-25-000102
    Q2 2025Quarterly · 2025-06-30ProductZILRETTA31,334,000USD0001396814-25-000102
    Q1 2025Quarterly · 2025-03-31ProductBupivacaine Liposome Injectable Suspension2,604,000USD0001628280-26-028871
    Q1 2025Quarterly · 2025-03-31ProductEXPAREL136,529,000USD0001628280-26-028871
    Q1 2025Quarterly · 2025-03-31ProductIovera5,123,000USD0001628280-26-028871
    Q1 2025Quarterly · 2025-03-31ProductRoyalty1,329,000USD0001628280-26-028871
    Q1 2025Quarterly · 2025-03-31ProductZILRETTA23,338,000USD0001628280-26-028871
    Q4 2024Quarterly · 2024-12-31ProductBupivacaine Liposome Injectable Suspension0USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductEXPAREL147,676,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductIovera6,454,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductRoyalty0USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductZILRETTA33,123,000USDLegacy provider
    FY 2024Yearly · 2024-12-31ProductBupivacaine Liposome Injectable Suspension7,322,000USD0001628280-26-012297
    FY 2024Yearly · 2024-12-31ProductEXPAREL548,962,000USD0001628280-26-012297
    FY 2024Yearly · 2024-12-31ProductIovera22,813,000USD0001628280-26-012297
    FY 2024Yearly · 2024-12-31ProductRoyalty3,780,000USD0001628280-26-012297
    FY 2024Yearly · 2024-12-31ProductZILRETTA118,089,000USD0001628280-26-012297
    Q3 2024Quarterly · 2024-09-30ProductBupivacaine Liposome Injectable Suspension1,643,000USD0001628280-25-050176
    Q3 2024Quarterly · 2024-09-30ProductEXPAREL132,004,000USD0001628280-25-050176
    Q3 2024Quarterly · 2024-09-30ProductIovera5,655,000USD0001628280-25-050176
    Q3 2024Quarterly · 2024-09-30ProductRoyalty851,000USD0001628280-25-050176
    Q3 2024Quarterly · 2024-09-30ProductZILRETTA28,420,000USD0001628280-25-050176
    FY 2023Yearly · 2023-12-31ProductBupivacaine Liposome Injectable Suspension3,342,000USD0001396814-24-000030
    FY 2023Yearly · 2023-12-31ProductCollaborative Licensing And Milestone Revenue0USD0001396814-24-000030
    FY 2023Yearly · 2023-12-31ProductEXPAREL538,120,000USD0001396814-24-000030
    FY 2023Yearly · 2023-12-31ProductIovera19,685,000USD0001396814-24-000030
    FY 2023Yearly · 2023-12-31ProductRoyalty2,733,000USD0001396814-24-000030
    FY 2023Yearly · 2023-12-31ProductZILRETTA111,098,000USD0001396814-24-000030
    FY 2021Yearly · 2021-12-31ProductBupivacaine Liposome Injectable Suspension3,606,000USD0001396814-24-000030
    FY 2021Yearly · 2021-12-31ProductCollaborative Licensing And Milestone Revenue125,000USD0001396814-24-000030
    FY 2021Yearly · 2021-12-31ProductEXPAREL506,515,000USD0001396814-24-000030
    FY 2021Yearly · 2021-12-31ProductIovera16,162,000USD0001396814-24-000030
    FY 2021Yearly · 2021-12-31ProductRoyalty2,442,000USD0001396814-24-000030
    FY 2021Yearly · 2021-12-31ProductZILRETTA12,683,000USD0001396814-24-000030
    FY 2020Yearly · 2020-12-31ProductBupivacaine Liposome Injectable Suspension4,459,000USD0001396814-23-000010
    FY 2020Yearly · 2020-12-31ProductCollaborative Licensing And Milestone Revenue0USD0001396814-23-000010
    FY 2020Yearly · 2020-12-31ProductEXPAREL413,338,000USD0001396814-23-000010
    FY 2020Yearly · 2020-12-31ProductIovera8,817,000USD0001396814-23-000010
    FY 2020Yearly · 2020-12-31ProductRoyalty3,033,000USD0001396814-23-000010
    FY 2020Yearly · 2020-12-31ProductZILRETTA0USD0001396814-23-000010
    FY 2019Yearly · 2019-12-31ProductBupivacaine Liposome Injectable Suspension3,153,000USD0001396814-22-000021
    FY 2019Yearly · 2019-12-31ProductEXPAREL407,877,000USD0001396814-22-000021
    FY 2019Yearly · 2019-12-31ProductIovera Member7,896,000USD0001396814-22-000021
    FY 2019Yearly · 2019-12-31ProductZILRETTA0USD0001396814-22-000021
    FY 2018Yearly · 2018-12-31ProductDepo Cyte0USD0001396814-20-000008
    FY 2018Yearly · 2018-12-31ProductEXPARELbupivacaineliposomeinjectablesuspension332,427,000USD0001396814-20-000008
    FY 2018Yearly · 2018-12-31ProductIovera Member0USD0001396814-20-000008
    FY 2017Yearly · 2017-12-31ProductDepo Cyte1,090,000USD0001396814-20-000008
    FY 2017Yearly · 2017-12-31ProductEXPARELbupivacaineliposomeinjectablesuspension283,252,000USD0001396814-20-000008
    FY 2017Yearly · 2017-12-31ProductIovera Member0USD0001396814-20-000008

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.